Management of acute upper gastrointestinal bleeding

Adrian J Stanley,1 Loren Laine2

ABSTRACT

Upper gastrointestinal bleeding (UGIB) is a common medical emergency, with a reported mortality of 2-10%. Patients identified as being at very low risk of either needing an intervention or death can be managed as outpatients. For all other patients, intravenous fluids as needed for resuscitation and red cell transfusion at a hemoglobin threshold of 70-80 g/L are recommended. After resuscitation is initiated, proton pump inhibitors (PPIs) and the prokinetic agent erythromycin may be administered, with antibiotics and vasoactive drugs recommended in patients who have cirrhosis. Endoscopy should be undertaken within 24 hours, with earlier endoscopy considered after resuscitation in patients at high risk, such as those with hemodynamic instability. Endoscopic treatment is used for variceal bleeding (for example, ligation for esophageal varices and tissue glue for gastric varices) and for high risk non-variceal bleeding (for example, injection, thermal probes, or clips for lesions with active bleeding or non-bleeding visible vessel). Patients who require endoscopic therapy for ulcer bleeding should receive high dose proton pump inhibitors after endoscopy, whereas those who have variceal bleeding should continue taking antibiotics and vasoactive drugs. Recurrent ulcer bleeding is treated with repeat endoscopic therapy, with subsequent bleeding managed by interventional radiology or surgery. Recurrent variceal bleeding is generally treated with transjugular intrahepatic portosystemic shunt. In patients who require antithrombotic agents, outcomes appear to be better when these drugs are reintroduced early.

Introduction

Upper gastrointestinal bleeding is a common medical emergency worldwide and refers to bleeding from the esophagus, stomach, or duodenum. Patients present with hematemesis (bloody or coffee ground emesis) or melena, although hematochezia can occur in the context of a major bleed and is typically associated with hemodynamic instability. Patients with melena present with lower hemoglobin values than patients with hematemesis, probably because presentation is more likely to be delayed.1 Therefore, patients with melena more often require transfusion, although mortality is lower in patients with melena than in those with hematemesis in some series.2 Numerous improvements in the management of upper gastrointestinal bleeding have been incorporated into clinical practice in recent years. However, many patients now have risk factors for a poorer outcome, including increasing age and major medical comorbidities.3

Although the cause of a bleeding episode is uncertain until endoscopy is undertaken, guidelines often separate upper gastrointestinal bleeding into variceal and non-variceal bleeding because management and outcomes differ.3,4 This article covers the acute management of patients with overt upper gastrointestinal bleeding, summarizing evidence for risk assessment, resuscitation, blood transfusion, medical and endoscopic therapy, and early post-endoscopic management. We will not review interventions for long term secondary prevention of bleeding, such as testing for and treating Helicobacter pylori infection, use of non-steroidal anti-inflammatory drugs (NSAIDs), or maintenance antisecretory therapy.

Upper gastrointestinal bleeding is managed by many clinicians across many specialties, including emergency room physicians, hospitalists, internists, gastroenterologists, surgeons, interventional radiologists, and hematologists.

A variety of topics—including risk assessment, the threshold for blood transfusion, the timing of endoscopy, and medical and endoscopic therapies—have continued to evolve in recent years. In addition, it has become increasingly important and complex to determine the appropriate management of patients who need antithrombotic agents, with gastroenterological, cardiovascular, and hematological aspects needing to be considered.

This article provides a comprehensive and evidence based summary of the assessment and management of patients with acute upper gastrointestinal bleeding, which is relevant to clinician specialists, academics, and clinical researchers. A summary of management is provided in the box.
STATE OF THE ART REVIEW

SUMMARY OF THE MANAGEMENT OF UPPER GASTROINTESTINAL BLEEDING

Pre-endoscopic management
- Hemodynamic assessment and resuscitation as needed
- Blood transfusion at a hemoglobin threshold of 70-80 g/L; higher threshold if severe bleeding with hypotension
- Risk assessment:
  - If Glasgow-Blatchford score ≤1 consider outpatient endoscopy and management
- Erythromycin (as a prokinetic agent) and proton pump inhibitor may be considered
- Patients with cirrhosis should receive vasoactive drugs and antibiotics

Endoscopic
- Endoscopy is generally recommended within 24 hours in patients admitted to hospital
  - If the patient has severe bleeding with hemodynamic instability, urgent endoscopy should be performed after resuscitation
- Ulcers with active bleeding and non-bleeding visible vessels should receive endoscopic therapy; endoscopic therapy may also be used for ulcers with adherent clots
- Injection therapy (eg, epinephrine), thermal probes (eg, bipolar electrocautery, heater probe), or clips should be used
- Epinephrine injection should always be followed by a second modality
- Recurrent bleeding should be treated with repeat endoscopic therapy but subsequent bleeding by transarterial embolization or surgery
- Esophageal variceal bleeding should be treated with ligation and gastric varices with the injection of tissue adhesive
- Refractory variceal bleeding should be treated with transjugular portosystemic shunt
- For massive refractory esophageal variceal bleeding a removable covered metal stent is preferred to balloon tamponade as a temporizing measure

Post-endoscopic management
- Patients who have ulcers with high risk lesions (active bleeding, visible vessel, adherent clot) should receive high dose proton pump inhibitors for 72 h
- Patients with cirrhosis should continue antibiotics for up to seven days regardless of the bleeding source
- Variceal bleeding should be treated with vasoactive drugs for up to five days
- When used for secondary prevention, aspirin should be continued or reintroduced soon after hemostasis is achieved
- Early reintroduction of other antithrombotic drugs is also recommended after hemostasis is achieved to reduce thrombotic events and death

Overall quality of evidence
Numerous randomized controlled trials (RCTs) and meta-analyses have assessed the use of medical and endoscopic therapy, and the optimal blood transfusion strategy in patients with acute upper gastrointestinal bleeding, thereby providing high quality data to guide management. Although the evidence regarding resuscitation, risk assessment, timing of endoscopy, and reintroduction of antithrombotic drugs is of lower quality, large recent studies in these areas have helped inform patient management.

Incidence
The incidence of upper gastrointestinal bleeding in the United Kingdom in the 1990s was 103-172/100,000 adults per year.10,11 Recent reports from the United States using nationwide administrative databases indicate that the incidence of hospital admission for the condition was 61-78 per 100,000 persons in 2009-2012.12,14 Peptic ulcers are the most common cause of hospital admission for upper gastrointestinal bleeding, accounting for just over half of all cases.12,14 The incidence of hospital admission for the condition has decreased 21-23% during the past 10 years.12,14 This decrease is largely accounted for by decreases in peptic ulcer bleeding (and bleeding ascribed to “gastritis”) probably because of the decreasing prevalence of H pylori and increasing use of antisecretory drugs. Case fatality rates from these database studies were low, in the range of 1.9-2.5%.12,14 By contrast, large observational cohort studies from Europe suggest higher fatality rates of around 10%.15,16 The reason for these differences is unknown but might be partly related to reliance on coding in database studies and differences in practice, such as low risk patients being more often managed in outpatient settings in Europe.

Sources and selection criteria
We searched PubMed, Medline, and Cochrane databases from 2010 to August 2018 using the search terms gastrointestinal hemorrhage, peptic ulcer bleeding, and variceal bleeding. References were also identified from the international, UK, European, American, and Asia-Pacific guidelines on upper gastrointestinal bleeding published during this period in addition to relevant review articles. We selected systematic reviews, meta-analyses, RCTs, and observational studies (excluding case reports and small (<15 cases) case series). We also excluded articles that were not peer reviewed and those not published in English. Studies were prioritized by design, as noted above, and by patient numbers, quality, and publication date.

Initial resuscitation
As with any new patient with a medical emergency, the initial clinical evaluation of patients presenting with upper gastrointestinal bleeding involves assessment of the patient’s airway, breathing, and circulation. Many patients are hemodynamically stable at presentation, but for those with major bleeding, early resuscitation is essential. In general, two large bore intravenous cannulae are inserted, although central venous access may be preferred in certain cases. Regular monitoring of pulse, blood pressure, and oxygen saturations is crucial. Hypotension is associated with increased mortality; a multicenter observational study of 1882 patients reported an odds ratio of 9.8 (95% confidence interval 5.1 to 19) with systolic blood pressure <90 mm Hg versus ≥90 mm Hg.11 Tracheal intubation may be used to protect the airway in patients with severe ongoing hematemesis, especially in those at increased risk of aspiration (such as those with an altered mental status or lack of gag reflex).

No RCTs have assessed fluid resuscitation in upper gastrointestinal bleeding. By contrast, a comparative study and an RCT in patients with hemorrhagic shock as a result of trauma suggest that a more restrictive fluid resuscitation may be better (or not worse) than more intensive fluid resuscitation.17,18 The choice of intravenous fluid for initial resuscitation is unclear, with crystalloids or colloids often being used while the need for the transfusion of blood products is assessed. A meta-analysis of 70 trials with 22,392 patients found no difference in mortality between colloid and crystalloid solutions for fluid resuscitation in critically ill patients: relative risk 1.01 (0.93 to 1.10) for albumin or plasma proteins versus crystalloid solutions, and similar negative results when other colloids were compared with crystalloids.19 An RCT of 15,802 critically ill hospital inpatients found reduced acute
kidney injury (odds ratio 0.91, 0.84 to 0.99) and a trend towards reduced mortality in hospital (10.3% v 11.1%; P=0.08) with balanced crystalloids versus saline. Whether these data can be fully extrapolated to upper gastrointestinal bleeding is uncertain.

Red blood cell transfusion

A meta-analysis of 31 RCTs comprising 12,587 patients in a variety of populations found that a more restrictive approach to red cell transfusion (variably defined at hemoglobin threshold 70-90 g/L) does not adversely affect outcomes; hospital mortality was lower with a restrictive strategy but 30 day mortality was not significantly different (risk ratio 0.97, 0.81 to 1.16). This systematic review concluded that a restrictive policy seemed to be safe in patients with underlying cardiovascular disease but no evidence was available for patients presenting with acute coronary syndrome. On that basis, current US guidelines recommend transfusion at a threshold of hemoglobin of 70 g/L for hemodynamically stable adult inpatients and 80 g/L for those undergoing orthopedic or cardiac surgery or with pre-existing cardiovascular disease. Others have suggested a threshold in patients with cardiovascular disease of ≥80 g/L. Importantly, results for the general populations described above may not be applicable to those with upper gastrointestinal bleeding. In such patients a restrictive transfusion approach appears not only to be safe but also to provide clinical benefit for rebleeding and mortality. A small study in 1986 first showed reduced rebleeding with restrictive transfusion. A large high quality Spanish RCT in 921 patients found significantly lower mortality at six weeks (hazard ratio 0.55, 0.33 to 0.92) and rebleeding (0.68, 0.47 to 0.98) with a transfusion hemoglobin threshold of 70 g/L versus 90 g/L. A subsequent six center cluster randomized feasibility trial in the UK reported no benefit from a liberal transfusion policy when hemoglobin thresholds of 80 g/L versus 100 g/L were compared (mortality difference −1%, −8% to 6% in 640 patients). A meta-analysis of five RCTs comprising 1965 patients with upper gastrointestinal bleeding reported that restrictive transfusion was associated with lower mortality (relative risk 0.65, 0.44 to 0.97) and reduced rebleeding (0.58, 0.40 to 0.84) (fig 1).

Thus, in most patients with upper gastrointestinal bleeding, red cell transfusion should be withheld until a hemoglobin threshold of 70-80 g/L is reached. Patients with severe bleeding and hemodynamic compromise, who were generally excluded from the trials described above, require transfusion at higher thresholds because their hemoglobin will equilibrate to much lower levels as their intravascular volume is repleted with fluid. Transfusion thresholds in patients with cardiovascular disease, especially those with acute coronary syndrome, are less certain, but thresholds of 80 g/L or higher are variably recommended.

Risk assessment

Many risk assessment scores have been developed for patients with upper gastrointestinal bleeding, including those that can be calculated early after presentation (pre-endoscopy) and those that include endoscopic findings. They were designed to predict a variety of endpoints. We believe pre-endoscopy scores are of greater practical use because it is probably most important to predict risk soon after presentation to help direct management. The use of risk scores has been recommended to stratify patients into those at higher or lower risk of poor outcomes.
Management of patients taking antithrombotic drugs

The increasing use of antithrombotic drugs (antithrombotic) medication in the management of cardiovascular disease means that many patients now presenting with upper gastrointestinal bleeding are taking these drugs. A recent multicenter observational study of 619 patients requiring endoscopic therapy for upper gastrointestinal bleeding reported that 44% were taking an antithrombotic drug at presentation, with 25% taking more than one.48 Although these drugs are a recognized risk factor for upper gastrointestinal bleeding, no clear evidence indicates that their use worsens outcomes after the bleed.49-51

The 2016 US guideline on management of antithrombotic agents for patients undergoing endoscopy suggests that platelet transfusion is an option for life threatening or serious bleeding in patients taking antplatelet agents.52 However, observational studies have failed to identify clinical benefit, and a cohort study with 408 patients showed significantly higher mortality with platelet transfusion (odds ratio 5.6, 1.5 to 27.1).53 This finding led the recent Asia-Pacific guideline panel to suggest that platelet transfusions should not be used in patients taking antplatelet agents who present with upper gastrointestinal bleeding.54 Platelet dysfunction may also be present in patients on hemodialysis or those who have had cardiac bypass surgery.55

Less information is available regarding the management of anticoagulants, including warfarin and the newer direct oral anticoagulants (DOACs), in patients with upper gastrointestinal bleeding. For patients taking warfarin, recent guidelines suggested the use of prothrombin complex concentrate (PCC) along with vitamin K to prevent rebound coagulopathy in patients with a life threatening bleed or hemodynamic instability.56 57 PCC is preferable
to fresh frozen plasma because of the smaller volume needed, its more rapid onset, lack of the need to check the patient’s blood group, and the minimal infectious risk. US guidelines suggest either four factor PCC plus vitamin K or fresh frozen plasma.54

Guidelines also suggest that the international normalized ratio (INR) should be corrected to <2.5 if possible before undertaking endoscopy, with the potential need for endoscopic therapy if the clinical situation allows.54 This suggestion is based on observational studies which indicate that the outcome after endoscopic therapy is similar in patients with an INR of 1.3–2.7 to that in those not taking warfarin.55 Other studies report that the INR value does not predict rebleeding.56

Data on DOACs are limited, but because of their short half lives (5–17 h), anticoagulant activity wanes rapidly over one to two days (in the absence of renal disease). Thus, European guidelines state that “time is the most important antidote against DOACs.” Although PCC may be of some use in severe bleeding, particularly for Xa inhibitors, neither vitamin K nor fresh frozen plasma has been shown to be beneficial.54 Reversal agents for dabigatran (idarucizumab)57 and the factor Xa inhibitors (andexanet alfa)58 are now approved in the US. Their role in patients with upper gastrointestinal bleeding is unclear given the uncertain risk of thrombotic events and the short half lives of DOACs. They would mainly be used in patients with a severe ongoing bleed, especially if DOAC ingestion was recent or if renal disease was present.

Coagulopathy and thrombocytopenia in patients with cirrhosis

Interpretation of the complex clotting abnormalities seen in cirrhosis can be difficult. Patients with cirrhosis have parallel decreases in procoagulant and anticoagulant factors.54 The prothrombin time measures procoagulant activity only; therefore, prothrombin time or INR is not a reliable indicator of coagulation status in patients with cirrhosis.55 Fresh frozen plasma is often given to patients with upper gastrointestinal bleeding, cirrhosis, and raised prothrombin time, but it has not been shown to provide benefit and could have adverse effects. For these reasons, the most recent US guidelines on portal hypertensive bleeding recommend against correcting INR with fresh frozen plasma or recombinant factor VIIa in patients with cirrhosis and acute variceal bleeding.59

Platelets from patients with cirrhosis generate thrombin in a similar way to those from healthy controls, and patients with cirrhosis have pro-hemostatic factors (increased von-Willebrand factor and decreased ADAMTS-13, a protease that cleaves von-Willebrand factor).54,55 However, patients with cirrhosis often have thrombocytopenia as a result of splenic sequestration. The experimental finding that a platelet count of 56×10^11/L leads to thrombin generation at the 10th centile of healthy control values56 provides the basis for giving platelet transfusions at around 50×10^11/L. However, no studies have assessed platelet thresholds or results with platelet transfusions, and some current guidelines state that no recommendation can be made regarding platelet transfusions.57

Pre-endoscopic medical therapy

The use of pre-endoscopic intravenous proton pump inhibitors (PPIs) has been assessed in several studies. A meta-analysis of six RCTs comprising 2223 patients found that the use of these drugs before endoscopy is associated with both reduced high risk stigmata of bleeding and the need for endoscopic therapy (odds ratio 0.68, 0.50 to 0.93) but has no effect on patient outcomes, including rebleeding, need for surgery, or mortality (1.12, 0.72 to 1.73).56 As a result, UK National Institute for Health and Care Excellence (NICE) guidelines do not support the routine use of these drugs before endoscopy.56 However, several other international guidelines suggest PPIs may have a role before endoscopy, particularly for patients in whom endoscopy may be delayed.54,28,57

Prokinetic agents have been assessed for their ability to improve gastric emptying, thereby improving visualization at endoscopy. Erythromycin, usually given as a 250 mg infusion 30–120 minutes before endoscopy, has been most widely studied. The most recent meta-analysis of 598 patients in eight RCTs showed improved visualization, reduced need for second look endoscopy, and reduced length of hospital stay (mean difference −1.75 days, 2.43 to −1.06) after erythromycin infusion before endoscopy.58

Tranexamic acid (TXA) inhibits the fibrinolytic activity of plasmin. A meta-analysis reported reduced mortality with TXA in patients with upper gastrointestinal bleeding, but many studies were of poor quality and had been undertaken before the widespread use of PPIs and endoscopic therapy.59 Furthermore, other outcomes such as bleeding episodes and transfusions were not reduced. Therefore, it is difficult to draw firm conclusions from these data. A meta-analysis of two RCTs comprising 40 138 patients with acute severe traumatic or postpartum bleeding suggested even a short delay in the administration of TXA reduces benefit: immediate treatment improved survival (odds ratio 1.72, 1.42 to 2.10), but survival fell 10% with every 15 minutes delay, with no benefit beyond three hours.60 A large international study (HALT-IT) will finish recruitment shortly and the results should help clarify the role of TXA in upper gastrointestinal bleeding.61

Pre-endoscopic medical therapy in patients with cirrhosis

Vasoactive drugs (terlipressin, somatostatin, or its analogs octreotide and vaptreotide), which cause splanchic artery vasoconstriction, are used in patients with cirrhosis and variceal bleeding. When combined with endoscopic therapy, the different vasoactive drugs seem to have similar efficacy.62 Three double blind RCTs examined the use of vasoactive drugs (terlipressin, somatostatin, and vaptreotide) given before endoscopy in patients with cirrhosis and upper gastrointestinal bleeding.63,64,65 Two studies reported less active bleeding at endoscopy in the active treatment group, but the third noted significantly more control of bleeding (clear gastric lavage and stable hemoglobin) at 12 hours with vasoactive drug therapy.65 Current guidelines recommend starting vasoactive drugs as soon as variceal hemorrhage is suspected.66
PPIs should not be given concurrently to patients who are receiving somatostatin (or analogs) because somatostatin provides inhibition of gastric acid secretion comparable to that provided by PPIs.\textsuperscript{66-68} Recommended doses are terlipressin 2 mg every four hours, somatostatin 250 μg bolus followed by 250-500 μg/h, and octreotide and vapreotide 50 μg bolus followed by 50 μg/h.\textsuperscript{9} These drugs are generally given for up to five days.\textsuperscript{66-69}

A meta-analysis of 12 RCTs compromising 1241 patients showed that antibiotics reduce infections, rebleeding, and mortality (relative risk 0.79, 0.63 to 0.98) in patients with cirrhosis and upper gastrointestinal bleeding.\textsuperscript{66} An RCT comparing intravenous ceftriaxone versus oral norfloxacin for seven days in 111 patients with advanced cirrhosis and gastrointestinal bleeding showed reduced proven infections with ceftriaxone (11% v 26%; P=0.03).\textsuperscript{69} However, the results may not be generalizable to all patients with cirrhosis because only 9% of screened patients were enrolled. Current guidelines suggest that antibiotics should be given from admission for up to seven days.\textsuperscript{68-69}

Intravenous ceftriaxone is preferred in patients with advanced cirrhosis or those taking quinolone prophylaxis and those in areas of high quinolone resistance, although the choice of antibiotic is dependent on local antimicrobial sensitivity patterns.\textsuperscript{66-69}

### Role of non-endoscopic diagnostic modalities before endoscopy

Because upper gastrointestinal bleeding can be diagnosed and treated with endoscopy, which is available in most hospitals, the role of other diagnostic modalities in patients presenting with an acute bleed is limited. In almost all cases, the initial diagnostic test will be upper endoscopy. Rarely, angiography or computed tomography is used in patients who are not candidates for endoscopy. However, these investigations are most commonly used if no source of bleeding is identified at endoscopy in patients with melena. A technetium-99m labelled red cell scan may also be used in this situation, but computed tomography angiography seems to be more accurate.\textsuperscript{70-71} Early use of capsule endoscopy has been reported, with goals including stratifying risk and determining the timing of endoscopy,\textsuperscript{72} but more studies are needed to establish any potential role.

### Timing of endoscopy

On the basis of improved outcomes in observational studies,\textsuperscript{5, 28} guidelines recommend that, after appropriate resuscitation, most patients who are admitted with upper gastrointestinal bleeding should undergo endoscopy within 24 hours. Some guidelines suggest that patients with hemodynamic compromise and those with cirrhosis, who may have varices, undergo endoscopy within 12 hours after presentation,\textsuperscript{5, 6, 8, 28} because some observational studies and subgroup analysis of an RCT provided limited evidence of improved outcome in high risk patients when endoscopy is performed within six to 13 hours.\textsuperscript{73-75} Features that have been considered high risk include GBS ≥8-12, bloody gastric lavage or persistent bloody emesis in hospital, hypotension, tachycardia, and comorbidities such as cirrhosis. However, evidence that can precisely identify high risk patients who should undergo early endoscopy is not available. In general, patients with persistent hemodynamic instability despite aggressive resuscitation will require urgent endoscopy.

Endoscopy should not be undertaken before the patient’s hemodynamic status is dealt with by initiating appropriate resuscitation and aiming to optimize comorbidities. This is illustrated by a recent observational study of 12,601 Danish patients with upper gastrointestinal bleeding secondary to peptic ulcers. This study suggested a survival benefit from delaying endoscopy for 12 hours in hemodynamically stable patients with American Society of Anesthesiologists score 3-5 (odds ratio 0.48, 0.34 to 0.67), and for six hours in patients with hemodynamic instability (0.73, 0.54 to 0.98) (fig 3).\textsuperscript{76} Most deaths after upper gastrointestinal bleeding are caused by underlying comorbidities rather than exsanguination, so attention to other medical problems is key to patient management.\textsuperscript{77}

Two small RCTs compared urgent (<2-6 h) with elective (>6 h) endoscopy for patients presenting with upper gastrointestinal bleeding who were hemodynamically stable and had no serious comorbidities.\textsuperscript{78-79} As expected in these low risk patients, no difference in clinical outcomes was identified. However, ~40-45% of patients had low risk endoscopic findings that would allow for early discharge. Thus, non-emergent endoscopy, undertaken as soon as possible within routine business hours, is recommended in low risk patients to allow safe early discharge in many of these patients.\textsuperscript{80}

### Endoscopic therapy

#### Non-variceal bleeding

Recommended modalities for ulcer bleeding include injection of epinephrine (eg, 1:10 000 dilution), injection
A meta-analysis of RCTs comparing PPIs to placebo or no therapy reported lower rates of further bleeding with an alternative modality (such as a thermal or mechanical) or to decrease the risk of inducing bleeding with the application of a second modality.

Most data on non-variceal upper gastrointestinal bleeding are from patients with peptic ulcer bleeding. The Forrest classification of endoscopic stigmata is commonly used by endoscopists to identify higher risk lesions that require the application of endoscopic therapy. Endoscopic therapy significantly decreases further bleeding and the need for urgent intervention in patients with ulcers with spurting or oozing blood (Forrest 1a or 1b) or with non-bleeding visible vessels (Forrest 2a; fig 4A). Patients with adherent clots (Forrest 2b) were not shown to benefit from endoscopic therapy in a meta-analysis of RCTs, but results of individual trials were very heterogeneous. This has led to guideline recommendations that either endoscopic plus medical therapy or medical management alone may be used for patients with adherent clots. Around 25-50% of patients admitted to hospital with bleeding ulcers have Forrest 1a, 1b, 2a, or 2b stigmata. Endoscopic treatment is not needed for ulcers with flat pigmented spots or a clean base (Forrest 2c or 3).

Variceal bleeding

Variceal bleeding accounted for 11% of patients admitted to hospital with acute upper gastrointestinal bleeding in a nationwide UK audit. However, the proportion of patients with variceal bleeding varies widely and is related to the proportion of people with liver disease in the population served. Patients with variceal bleeding have a higher mortality than those with non-variceal bleeding, and this is largely related to the severity of underlying liver disease.

The optimal endoscopic therapy for esophageal variceal bleeding is variceal band ligation, which is associated with less rebleeding and fewer side effects than sclerotherapy. If gastric varices are found, ligation can be used for gastroesophageal varices type-1, where esophageal varices extend several centimeters distally along the gastric lesser curve. Injection of tissue adhesive (eg, N-butyl-cyanoacrylate) is the recommended endoscopic approach for all other types of gastric varices, although thrombin injection can be considered. Thrombin injection has been described for gastric variceal bleeding in cohort studies, but to date no RCTs have compared it with other treatments.

Post-endoscopic management

PPI therapy

A meta-analysis of RCTs comparing PPIs to placebo or no therapy in high risk patients undergoing successful endoscopic therapy showed that high dose PPIs, usually given as an intravenous bolus of 80 mg followed by continuous infusion at 8 mg/h for 72 hours, reduced rebleeding (relative risk 0.60, 0.28 to 0.93) and mortality (0.41, 0.20 to 0.84). Intermittent intravenous or oral PPIs reduced rebleeding (0.53, 0.35 to 0.78) but not mortality.
state of the art review

meta-analysis of 13 studies found that a bolus followed by intermittent doses of intravenous or oral PPIs was non-inferior to continuous infusion (further bleeding risk ratio 0.72; one sided 95% confidence interval upper boundary 0.97), although most individual studies were relatively small and not designed to answer this question. No conclusions could be made regarding oral versus intravenous dosing, although oral administration provides an antisecretory effect comparable to equivalent doses of intravenous PPIs. Guidelines have recommended an intravenous bolus followed by continuous infusion PPI therapy, although recent guidelines also suggest considering intermittent high doses of oral or intravenous PPI (eg, 80-160 mg daily in divided doses after an initial 80 mg bolus), rather than continuous infusion.

Patients with peptic ulcer bleeding generally receive four to eight weeks of once daily oral PPIs. Those with low risk endoscopic lesions (clean base, flat spot) should receive PPIs once a day from the time of diagnosis. Those with high risk endoscopic lesions and clinical features should receive high dose PPIs on days one to three as above, followed by twice daily oral PPI on days four to 14. This regimen is based on an RCT of 187 patients that showed significantly less rebleeding with twice daily versus once daily PPIs (relative risk 0.41, 0.18 to 0.93) during this period. The benefits of PPIs outweigh potential risks when used after bleeding from a peptic ulcer. Multiple pharmacodynamics studies report that omeprazole reduces the antiplatelet effect of clopidogrel, but a double blind placebo controlled trial in 3761 clopidogrel users found no evidence that omeprazole increased cardiovascular events (hazard ratio 0.99, 0.68 to 1.44). The US Food and Drug Administration recommends avoiding the use of omeprazole or esomeprazole in patients who are taking clopidogrel.

Patients with cirrhosis and variceal bleeding

As noted above, in patients with cirrhosis and upper gastrointestinal bleeding, antibiotics should be continued for up to seven days, regardless of whether varices are identified as the source of the bleeding. Patients who have documented variceal bleeding at endoscopy should also have their vasoactive drugs continued for up to five days. Combined treatment with endoscopic ligation and vasoactive drugs is superior to ligation alone or vasoactive drugs alone in reducing further bleeding in hospital or during the first seven days after treatment.

Transjugular intrahepatic portosystemic shunt (TIPS) may also be used after initial endoscopic therapy in the first three days after presentation for the treatment of acute esophageal variceal bleeding in patients with Child-Pugh class C cirrhosis (score 10-13). A multicenter RCT compared early (within 72 h) TIPS placement versus standard treatment with variceal ligation plus drug therapy in 63 patients with Child-Pugh C cirrhosis or Child-Pugh B cirrhosis with active bleeding. It reported that more patients were free from further bleeding at one year with early TIPS (97% vs 50%; P<0.001). One year survival was also higher with early TIPS (86% vs 61%; P<0.001) and encephalopathy was not increased. Subsequent reports suggest that the benefit is primarily in those with Child-Pugh C disease. However the evidence for early TIPS remains relatively limited and the practicalities may be challenging for many units.

Reintroduction of antithrombotic drugs

Several studies suggest a survival benefit from continuing or reintroducing antithrombotic drugs after upper gastrointestinal bleeding. This is perhaps unsurprising given that mortality after presentation with a bleed is more often caused by underlying comorbidities, particularly cardiovascular disease, rather than the bleed itself. However, balancing the risks and benefits of reintroducing these drugs after a patient presents with upper gastrointestinal bleeding can be challenging. If an antithrombotic drug is reintroduced, a PPI is usually also administered.

Aspirin is the most widely studied antithrombotic drug in patients with upper gastrointestinal bleeding. Stratification of patients must be based on whether aspirin is given for secondary or primary cardiovascular prevention. This is because the benefit in secondary prevention is far greater than that for primary prevention, with a number needed to treat to prevent myocardial infarction, stroke, or vascular death of 67 versus 1745.

A randomized study of 156 patients with peptic ulcer bleeding who had been taking aspirin for secondary prevention reported reduced mortality at eight weeks in those who continued aspirin compared with those who discontinued the drug (1.3% vs 12.9%; difference 11.6%, 3.7% to 19.5%). Therefore, current guidelines suggest continuing aspirin (or reintroducing the drug within three days for higher risk endoscopic lesions) once hemostasis is achieved. It has been suggested that when aspirin has been prescribed for primary prophylaxis, it should be stopped in most patients because the bleeding risk probably outweighs the cardiovascular benefit. If primary prevention is still clinically required after the bleed, it can be reintroduced after the ulcer has healed, or earlier depending on the clinical situation.

No randomized studies are available to guide clinicians on the reintroduction of thienopyridines (eg, clopidogrel) or anticoagulants. Recent guidelines suggest that for patients receiving dual antiplatelet therapy, at least one drug, usually aspirin, should be reintroduced early as above, with the second drug withheld for up to five days after hemostasis, or the timing discussed with a cardiovascular specialist.

Transjugular intrahepatic portosystemic shunt (TIPS) may also be used after initial endoscopic therapy in the first three days after presentation for the treatment of acute esophageal variceal bleeding in patients with Child-Pugh class C cirrhosis (score 10-13). A multicenter RCT compared early (within 72 h) TIPS placement versus standard treatment with variceal ligation plus drug therapy in 63 patients with Child-Pugh C cirrhosis or Child-Pugh B cirrhosis with active bleeding. It reported that more patients were free from further bleeding at one year with early TIPS (97% vs 50%; P<0.001). One year survival was also higher with early TIPS (86% vs 61%; P<0.001) and encephalopathy was not increased. Subsequent reports suggest that the benefit is primarily in those with Child-Pugh C disease. However the evidence for early TIPS remains relatively limited and the practicalities may be challenging for many units.

Reintroduction of antithrombotic drugs

Several studies suggest a survival benefit from continuing or reintroducing antithrombotic drugs after upper gastrointestinal bleeding. This is perhaps unsurprising given that mortality after presentation with a bleed is more often caused by underlying comorbidities, particularly cardiovascular disease, rather than the bleed itself. However, balancing the risks and benefits of reintroducing these drugs after a patient presents with upper gastrointestinal bleeding can be challenging. If an antithrombotic drug is reintroduced, a PPI is usually also administered.

Aspirin is the most widely studied antithrombotic drug in patients with upper gastrointestinal bleeding. Stratification of patients must be based on whether aspirin is given for secondary or primary cardiovascular prevention. This is because the benefit in secondary prevention is far greater than that for primary prevention, with a number needed to treat to prevent myocardial infarction, stroke, or vascular death of 67 versus 1745.

A randomized study of 156 patients with peptic ulcer bleeding who had been taking aspirin for secondary prevention reported reduced mortality at eight weeks in those who continued aspirin compared with those who discontinued the drug (1.3% vs 12.9%; difference 11.6%, 3.7% to 19.5%). Therefore, current guidelines suggest continuing aspirin (or reintroducing the drug within three days for higher risk endoscopic lesions) once hemostasis is achieved. It has been suggested that when aspirin has been prescribed for primary prophylaxis, it should be stopped in most patients because the bleeding risk probably outweighs the cardiovascular benefit. If primary prevention is still clinically required after the bleed, it can be reintroduced after the ulcer has healed, or earlier depending on the clinical situation.

No randomized studies are available to guide clinicians on the reintroduction of thienopyridines (eg, clopidogrel) or anticoagulants. Recent guidelines suggest that for patients receiving dual antiplatelet therapy, at least one drug, usually aspirin, should be reintroduced early as above, with the second drug withheld for up to five days after hemostasis, or the timing discussed with a cardiovascular specialist.

Similar to the situation with antiplatelet agents, observational studies in patients who develop upper gastrointestinal bleeding while taking warfarin indicate that those who restart warfarin have markedly lower rates of death and thromboembolic events, without a higher rate of recurrent bleeding, when compared with those whose warfarin is not restarted. Recent guidelines suggest restarting warfarin from “as soon as hemostasis is established” to seven to 15 days after the bleeding event. The indication for anticoagulation should be assessed at the time of the bleed, with early reintroduction (zero to seven days) recommended in patients with a higher thromboembolic risk. However, robust data on the optimal timing of reintroduction are not available.
Data on the timing of the reintroduction of DOACs after bleeding has been controlled are limited, and this clearly depends on the balance of risk between rebleeding and thromboembolic events. Use of the CHA2DS2-VASC (Congestive heart failure, Hypertension, Age-2, Diabetes, Stroke/TIA-2, Vascular disease) and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, prior Bleeding, Labile INRs, Elderly (>65 years), Drugs and alcohol) scores may help in this situation.\textsuperscript{108-110} The recent Asia-Pacific guidelines suggest reintroducing DOACs in patients with a high thromboembolic risk as soon as hemostasis is achieved, although others have suggested that patients should have their anticoagulant restarted at day 7, with possible bridging therapy with low molecular weight heparin from days 2 to 7 in those with a low bleeding risk.\textsuperscript{5} In general, patients with an increased thromboembolic risk should have early reintroduction of antithrombotic drugs, because the risks and severity of thromboembolic events generally outweigh those of bleeding events.

**Management of persistent or recurrent bleeding, including role of interventional radiology and surgery**

**Non-variceal bleeding**

The results of an RCT comparing repeat endoscopic therapy with surgery in 92 patients with recurrent peptic ulcer bleeding indicate that endoscopic therapy should be repeated when bleeding recurs after initial endoscopic control.\textsuperscript{111} This study reported similar mortality, although more patients had complications with surgery (36.4% vs 14.6%; P=0.03). For patients with persistent or refractory bleeding from non-variceal sources despite optimal standard endoscopic and medical therapy, the addition of hemostatic powder spray for temporary control (12-24 h) or over-the-scope clips (OTSC) as a rescue modality is suggested, in parallel with ongoing resuscitation.\textsuperscript{116,112,113}

For peptic ulcer bleeding not controlled by endoscopic therapy, two recent meta-analyses of observational studies that compared surgery with radiological intervention reported lower rebleeding with surgery, but similar mortality and need for further interventions, although patients receiving radiological intervention were older and in worse general health.\textsuperscript{114,115} Because many patients with recurrent bleeding are elderly with comorbidities, interventional radiology is generally preferred if locally available. Therefore, if bleeding continues despite optimal endoscopic therapy, transarterial embolization is recommended, although surgery should be considered if radiological therapy is likely to be delayed.\textsuperscript{115}

Prophylactic transarterial embolization of high risk ulcers after endoscopic therapy is not recommended: it did not significantly reduce rebleeding when compared with standard treatment (10.2% vs 11.4%) in an RCT of 241 patients.\textsuperscript{116}

**Variceal bleeding**

Patients with rebleeding after initial endoscopic and medical therapy for varices may have repeat endoscopic therapy performed.\textsuperscript{7} TIPS is recommended for those with persistent or severe recurrent bleeding.\textsuperscript{7,9} For patients with severe bleeding refractory to endoscopic therapy, balloon tamponade has been recommended as a temporary bridge to definitive therapy.\textsuperscript{7,8} However, balloon tamponade is associated with serious complications (such as esophageal rupture and aspiration pneumonia) in about 12% of patients and its use was lethal in 6% of patients in a case series.\textsuperscript{117} Recently, removable self expanding covered metal esophageal stents designed for the treatment of severe esophageal variceal bleeding have become available (although they are not approved in the US). An RCT of 28 patients compared these stents with balloon tamponade in patients with esophageal variceal bleeding refractory to medical and endoscopic therapy and showed that the stents led to improved bleeding control (85% vs 47%; Fisher’s exact test P=0.055), with similar mortality.\textsuperscript{118}

**Emerging treatments**

**Hemostatic powder spray**

Hemostatic powder spray provides high rates of initial hemostasis for active non-variceal upper gastrointestinal bleeding, but with relatively high rebleeding rates, suggesting a temporary effect.\textsuperscript{119-121} A systematic review of 195 cases reported initial hemostasis in 92% and a seven day rebleeding rate of 21%.\textsuperscript{122} Currently, hemostatic powder is often used as a temporary rescue treatment for bleeding that cannot be controlled using established methods, and it may have a role for the initial control of diffuse bleeding from tumors.\textsuperscript{6,112} More limited data are available on hemostatic powder spray for variceal bleeding, often as a temporizing method until definitive therapy is applied.\textsuperscript{124}

**Over-the-scope clips**

Treatment with OTSC is another relatively new technique. These clips are much larger than standard through-the-scope clips so may be successful when applied to larger fibrotic lesions or larger feeding vessels. A multicenter RCT of 66 patients with recurrent ulcer bleeding after initial hemostasis showed that significantly fewer patients treated with OTSC had further bleeding compared with those on standard therapy (15% vs 58%; difference 42%, 22% to 63%).\textsuperscript{122} Further data are awaited, but at present OTSC may be considered as a rescue therapy when standard therapies do not achieve permanent hemostasis.

**Doppler probes**

Endoscopic Doppler probes have also been studied as a guide to endoscopic therapy. A recent dual center RCT of 148 patients with severe non-variceal upper gastrointestinal bleeding that compared endoscopic therapy guided by Doppler probe positive signals with standard endoscopic therapy guided by endoscopic stigmata found reduced 30 day rebleeding with Doppler guided therapy (11.1% vs 26.3%; P=0.02).\textsuperscript{125} Further data on the clinical utility and practicalities of this approach are needed, and currently the use of these probes is not recommended by guidelines.\textsuperscript{5,6}

**Guidelines**

As already noted, international, UK (NICE), American, European, and Asia-Pacific guidelines on upper gastro-
Recommendations from major published guidelines on non-variceal UGIB

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Risk scoring</th>
<th>Prokinetics</th>
<th>Pre-endoscopy PPIs</th>
<th>Timing of endoscopy</th>
<th>Post-endoscopy PPIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>International, 2010</td>
<td>Prognostic scales recommended to identify high and low risk groups</td>
<td>Promotility agents should not be used routinely</td>
<td>May be considered but should not delay endoscopy</td>
<td>Within 24 h for most patients</td>
<td>IV PPI bolus then infusion if high risk stigmata and have had successful endoscopic therapy</td>
</tr>
<tr>
<td>US, ACG (ulcer bleeding only) 2012</td>
<td>Carry out risk assessment to stratify into higher and lower risk groups. Consider discharge from ED if GBS=0</td>
<td>Consider IV erythromycin</td>
<td>IV/PPIs may be considered</td>
<td>Within 24 h after resuscitation. Consider within 12 h if high risk features (e.g., hemodynamic instability, bloody emesis in hospital)</td>
<td>After successful endoscopic hemostasis, give IV/PPI bolus then infusion to those with active bleeding, NRBP or adherent clot</td>
</tr>
<tr>
<td>US, ASGE 2012</td>
<td>No specific recommendation but notes that GBS=0 identifies a very low risk group</td>
<td>Suggest IV prokinetic (high probability of fresh blood or clot in stomach)</td>
<td>IV/PPIs recommended</td>
<td>Depends on clinical factors but recommends within 24 h in the presence of cancer, cirrhosis, hematemesis, hypovolemia, or Hb &lt;80 g/L</td>
<td>IV PPI bolus then infusion after endoscopic therapy for ulcers with high risk stigmata</td>
</tr>
<tr>
<td>UK, NICE 2012</td>
<td>Use GBS before endoscopy and full Rockall score after endoscopy. Consider early discharge if GBS=0</td>
<td>Not assessed</td>
<td>Do not give PPIs before endoscopy</td>
<td>Within 24 h, but immediately after resuscitation if unstable and severe UGIB</td>
<td>Offer PPIs if stump of recent bleeding seen at endoscopy</td>
</tr>
<tr>
<td>Europe, ESGE 2015</td>
<td>Patients with GBS 0-1 do not require early endoscopy or admission</td>
<td>Recommend IV erythromycin if clinically severe or ongoing active UGIB</td>
<td>IV/bolus then infusion but should not delay endoscopy</td>
<td>Within 24 h if resuscitation, but consider within 12 h if high risk features (e.g., hemodynamic instability despite resuscitation, inpatient bloody emesis, contraindication to stopping anticoagulants)</td>
<td>IV PPI bolus then 72 h infusion for patients who receive endoscopic hemostasis and those with adherent clots. Consider giving PPIs as intermittent IV bolus or high dose oral</td>
</tr>
<tr>
<td>Asia-Pacific, 2018</td>
<td>Use GBS, adopting a cut off at GBS ≤1 allows most hospitals to reduce unnecessary admissions</td>
<td>Not assessed</td>
<td>IV/PPIs recommended if suspected UGIB awaiting endoscopy (especially if endoscopy is not available within 24 h)</td>
<td>Within 24 h, but urgent (within 12 h) if hemodynamic instability, after resuscitation and stabilization</td>
<td>After endoscopic hemostasis is achieved high dose oral PPIs can be used for 72 h as an alternative to high dose IV PPIs</td>
</tr>
</tbody>
</table>

Abbreviations: ACG=American College of Gastroenterology; ASGE=American Society for Gastrointestinal Endoscopy; ED=emergency department; ESGE= European Society of Gastrointestinal Endoscopy; GBS=Glascow Blatchford score; Hb=hemoglobin; NRBP=non-bleeding visible vessel; NICE=National Institute for Health and Care Excellence; PPIs=proton pump inhibitors; IV=intravenous; UGIB=upper gastrointestinal bleeding.

QUESTIONS FOR FUTURE RESEARCH

- What is the optimal approach to fluid resuscitation in patients with acute upper gastrointestinal bleeding?
- Can risk assessment tools be developed to allow accurate early identification of high risk patients with upper gastrointestinal bleeding, such as those who require endoscopic therapy or those with high mortality?
- What is the optimal timing of endoscopy after upper gastrointestinal bleeding?
- What is the exact role of hemostatic powder spray, over-the-scope clips, and Doppler ultrasound probes in the endoscopic management of upper gastrointestinal bleeding?
- When is the best time to reintroduce antithrombotic drugs after upper gastrointestinal bleeding?

Intestinal bleeding (non-variceal and variceal) have been published over the past eight years. We have therefore referenced them as appropriate throughout. The most recent ones—the European (2015) and Asia-Pacific (2018) guidelines on non-variceal bleeding, and the UK, international, and US guidelines on variceal bleeding—differ slightly from earlier ones, largely because they assessed more recently published studies (table). These guidelines have generally been written by experts in this field, although methodology has varied.

Conclusions

Upper gastrointestinal bleeding remains a common cause of presentation to hospitals worldwide, and many recent studies have assessed the management of patients with this condition. The evidence of improved outcomes from a relatively restrictive approach to blood transfusion and the ability to identify patients who are at very low risk and suitable for outpatient management have recently altered clinical practice, and these alterations to management are now recommended by international guidelines. RCTs and meta-analyses confirm a benefit from pre-endoscopy antibiotics and vasoactive drugs in patients with cirrhosis, and post-endoscopy high dose PPIs for high risk peptic ulcer bleeding.

Endoscopic therapy has advanced dramatically over the past decades, with recent additions to the endoscopist’s “toolkit,” including hemostatic powder spray, over-the-scope clips, and Doppler probes. These join the established and widely studied injection therapies, thermal probes, and clips used for non-variceal bleeding, and endoscopic band ligation and tissue adhesive injection for variceal bleeding. However, the newer modalities require further study to clarify their exact role in endoscopic management. Technical improvements and more widely available services for interventional radiology have led to it being the most commonly used rescue therapy for persistent or recurrent upper gastrointestinal bleeding that is refractory to endoscopic treatment. Surgery is now typically reserved for situations in which interventional radiology is unavailable, delayed, or unsuccessful.

The more widespread use of antiplatelet and anticoagulants drugs has led to uncertainty in managing patients taking these medications who develop upper gastrointestinal bleeding. However, recent data suggest that relatively early reintroduction of these drugs once hemostasis has been achieved is the best approach in those with appropriate cardiovascular indications. New approaches under investigation for managing upper gastrointestinal bleeding include the early use of TXA and novel endoscopic techniques to reduce rebleeding. These and other developments will hopefully continue to improve management and outcomes for patients with upper gastrointestinal bleeding.
STATE OF THE ART REVIEW

HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS ARTICLE

After email communication from the UK Gastroenterology Charity “Guts-UK” (previously CORE) to their members and related charities, three patients kindly volunteered to review the manuscript. In response to their comments, the sections on blood transfusion and timing of endoscopy were revised.

Thanks to Deepak Vishwanath for help with the radiological image in fig 4.

Contributors

Thanks to Deepak Vishwanath for help with the radiological image in fig 4.

55
53
51
46
43
42

pmid:29705263.

variceal hemorrhage.
controlled trial.
Lancet
2006;44:440-5.

pmid:27366031.
administration in upper gastrointestinal bleeding: an updated meta-
upper GI bleeding.
Hwang JH, Fisher DA, Ben-Menachem T, et al. Standards of Practice
id:20614440.
treatment initiated prior to endoscopic diagnosis in upper gastrointestinal
Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in
NEJMoa1607887  pmid:27573206.
Xa inhibitors.

reversal—full cohort analysis.
Gastrointestinal Endoscopy (ESGE) guidelines.
agents.
transfusion for gastrointestinal bleeding in patients taking antiplatelet
Zakko L, Rustagi T, Douglas M, Laine L. No benefit from platelet
patients undergoing GI endoscopy.

agents reduces mortality and length of hospital stay in patients with
Dunne PDJ, Laursen SB, Laine L, et al. Previous use of antithrombotic
agents on the site
10.1080/00365520510015458  pmid:16036503.

37. 10.1093/bmj.l536 on 25 March 2019. Downloaded from

For personal use only
For personal use only

STATE OF THE ART REVIEW


10.1136/bmj.l536 on 25 March 2019. Downloaded from http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from